Anika Therapeutics Announces Top-Line Results from CINGAL Trial in Knee OA

Anika Therapeutics announced results from the Phase III clinical trial of CINGAL® to support U.S. registration. A previous placebo-controlled Phase III trial demonstrated safety and efficacy through 26 weeks, while the current trial compared CINGAL, a combination of cross-linked HA and triamcinolone hexacetonide (TH), with TH alone and...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us